Bevacizumab in colorectal cancer: it should have worked
Mené dans 7 pays sur 1 952 patients atteints d'un cancer colorectal de stade II à haut risque de récidive ou de stade III, cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans maladie à 3 ans, et la toxicité de l'ajout du bévacizumab à la capécitabine en traitement adjuvant (durée médiane de suivi : 4,9 ans)
We've heard the message before: until we do the trial, we don't know the result, and negative trials, unwelcome as they are, are just as important as positive ones. In The Lancet Oncology, Rachel Kerr and colleagues present the results of the QUASAR 2 trial,1 which now joins the NSABP C-082 and AVANT3 trials as an important negative study of bevacizumab. Kerr and coworkers assessed capecitabine alone versus capecitabine plus bevacizumab as adjuvant treatment after potentially curative surgery for histologically proven stage III or high-risk stage II colorectal cancer.
The Lancet Oncology , commentaire, 2015